Nurix Therapeutics, Inc. $NRIX Position Trimmed by Intech Investment Management LLC

Intech Investment Management LLC decreased its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 25.4% during the second quarter, Holdings Channel.com reports. The firm owned 42,353 shares of the company’s stock after selling 14,417 shares during the period. Intech Investment Management LLC’s holdings in Nurix Therapeutics were worth $482,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in NRIX. Creative Planning purchased a new position in Nurix Therapeutics during the second quarter valued at approximately $187,000. Police & Firemen s Retirement System of New Jersey boosted its stake in shares of Nurix Therapeutics by 16.2% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 18,104 shares of the company’s stock valued at $206,000 after buying an additional 2,522 shares during the period. Geode Capital Management LLC boosted its stake in shares of Nurix Therapeutics by 9.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,881,960 shares of the company’s stock valued at $21,437,000 after buying an additional 157,592 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of Nurix Therapeutics during the 2nd quarter valued at $215,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd increased its stake in shares of Nurix Therapeutics by 85.3% in the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 26,406 shares of the company’s stock worth $301,000 after acquiring an additional 12,157 shares during the last quarter.

Nurix Therapeutics Stock Performance

Shares of NASDAQ NRIX opened at $17.68 on Friday. The business’s 50-day simple moving average is $11.71 and its 200-day simple moving average is $11.12. Nurix Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $23.00. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of -5.95 and a beta of 2.30.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Thursday, October 9th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.19). Nurix Therapeutics had a negative return on equity of 53.57% and a negative net margin of 292.50%.The company had revenue of $7.89 million during the quarter, compared to analyst estimates of $16.06 million. As a group, equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 6,284 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $12.56, for a total transaction of $78,927.04. Following the completion of the transaction, the chief financial officer owned 37,592 shares of the company’s stock, valued at $472,155.52. The trade was a 14.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Gwenn Hansen sold 4,087 shares of the company’s stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $12.80, for a total transaction of $52,313.60. Following the sale, the insider owned 76,751 shares of the company’s stock, valued at $982,412.80. This trade represents a 5.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 13,501 shares of company stock valued at $171,305. 7.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on NRIX shares. Stifel Nicolaus set a $33.00 price objective on Nurix Therapeutics in a report on Friday, October 10th. Mizuho started coverage on Nurix Therapeutics in a research report on Tuesday, October 21st. They issued an “outperform” rating and a $24.00 target price on the stock. Baird R W raised Nurix Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 26th. Wall Street Zen cut Nurix Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, October 11th. Finally, Morgan Stanley dropped their price objective on Nurix Therapeutics from $16.00 to $15.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 14th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $26.88.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.